Systemic lupus erythematosus

Medicine

Volumn 38, Issue 2, 2010, Pages 73-80

  Gordon, Caroline ^a,b,c   Li, Charles K ^a,b,c   Isenberg, David A ^a,b,c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

B cell depletion; dsDNA autoantibody; mycophenolate; systemic lupus erythematosus; UV light

Indexed keywords

ABATACEPT; ALPHA INTERFERON; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; C REACTIVE PROTEIN; CALCIUM; COMPLEMENT COMPONENT C1Q; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DAPSONE; DOUBLE STRANDED DNA; HYDRALAZINE; HYDROXYCHLOROQUINE; METHOTREXATE; MINOCYCLINE; MYCOPHENOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PHOSPHOLIPID ANTIBODY; PRASTERONE; PREDNISOLONE; PROCAINAMIDE; RITUXIMAB; SINGLE STRANDED DNA; THEOPHYLLINE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VITAMIN D;

AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE CLASSIFICATION; ENVIRONMENTAL FACTOR; EXERCISE; EYE TOXICITY; GASTROINTESTINAL DISEASE; HEART DISEASE; HEMATOLOGY; HEREDITY; HUMAN; HYPERSENSITIVITY REACTION; KIDNEY DISEASE; LIFESTYLE MODIFICATION; LUNG DISEASE; LUPUS LIKE SYNDROME; MORBIDITY; MORTALITY; MUSCULOSKELETAL DISEASE; NEUROPSYCHIATRY; NUCLEOSOME; PATHOGENESIS; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEX RATIO; SURVIVAL; SYSTEMIC LUPUS ERYTHEMATOSUS; VITAMIN SUPPLEMENTATION;

EID: 75949097841     PISSN: 13573039     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mpmed.2009.10.006     Document Type: Review

References (9)

1. Sanchez-Guerrero J., Karlson E.W., Liang M.H., Hunter D.J., Speizer F.E., and Colditz G.A. Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. Arthritis Rheum 40 (1997) 804-808
2. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
3. Salmon M., and Gordon C. The role of apoptosis in systemic lupus erythematosis. Rheumatology 38 (1999) 1177-1183
4. Karrar A., Sequeira W., and Block J.A. Coronary artery disease in systemic lupus erythematosus: a critical review of the epidemiological evidence. Semin Arthritis Rheum 30 (2001) 436-443
5. Sultan S.M., Ioannou Y., and Isenberg D.A. A review of gastrointestinal manifestations of systemic lupus erythematosus. Rheumatology 38 (1999) 917-932
6. Weening J.J., D'Agati V.D., Schwartz M.M., et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15 (2004) 241-250
7. Howie A.J., Turhan H., and Adu D. Powerful morphometric indicator of prognosis in lupus nephritis. Q J Med 6 (2003) 411-420
8. Griffiths B., Mosca M., and Gordon C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol 19 (2005) 685-708
9. Lu T.Y., Ng K.P., Cambridge G., et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London hospital: the first fifty patients. Arthritis Rheum 61 (2009) 482-487